Markets Earnings Screener Watchlist

Fundamentals and filings are sourced from SEC EDGAR. Market data, ownership and analyst consensus are sourced from Nasdaq. Written analysis is generated by metir from those sources and the linked reporting.

All information is provided for informational purposes only. It is not investment, financial, tax or legal advice, is not a recommendation to buy or sell any security, and is not intended for trading purposes. Data may be delayed or incomplete.

DexCom, Inc. Stock Price: Quote, Financials, Forecast & News (DXCM)

Markets open

DexCom, Inc.

DXCM · Nasdaq

Overview Financials Earnings Holders Historical Data Analysis

$84.13-$2.813.23%

As of: Aug 5, 2:40 PM

Prev Close: $86.94
Market Cap: $31.75B
Open: —
Trailing P/E: —
Day Range: $85.78 - $82.79
52W Range: $87.85 - $54.11
Forward P/E: —
EPS: —
Volume: 1.69M
Dividend Yield: —

Notable Price Movement

Weekly movement commentary will appear here once it has been generated for this company.

Stories & Analysis

DXCM Crosses Above Average Analyst Target

BNK Invest · 1d ago

DexCom (DXCM) Q2 2026 Earnings Call Transcript

The Motley Fool · 2d ago

Stocks Finish Higher as Amazon Leads Megacaps Higher

Barchart · 2d ago

DexCom (DXCM) Recently Broke Out Above the 20-Day Moving Average

Zacks · 2d ago

Best Health & Fitness Stocks for Investors Amid Wellness Boom

Zacks · 2d ago DexCom, Inc. (DXCM) Hit a 52 Week High, Can the Run Continue?

Zacks · 2d ago Stock Indexes Supported as Amazon Earnings Bolster Tech Stocks

Barchart · 5d ago Stocks Turn Mixed as Bond Yields Jump

Barchart · 5d ago

Symbol: DXCM
Type: Stock
Sector: Health Care
Industry: Medical/Dental Instruments
Country: North America
Exchange: Nasdaq

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Analyst Consensus

Buy

21 analysts

$84

Current

—

Low

$90

Average

—

High

Average target implies +6.98% versus the current price.

Earnings History

BeatMissNo estimate

Peers

ResMed Inc.RMD · NYSE$223.67

0.24%

Becton, Dickinson and CompanyBDX · NYSE$170.540.25%

Medline Inc.MDLN · Nasdaq$36.0314.30%

Boston Scientific CorporationBSX · NYSE$48.102.02%

Beta

—

Avg Volume

5.20M